Three-year findings from a sirolimus-eluting bioresorbable vascular scaffold (BVS) for the treatment of infrapopliteal lesions show great primary patency rates in lesions with an average lesion length of 3cm and a high rate of freedom from clinically-driven target lesion revascularisation.

Dr Michel Bosiers (Inselspital Bern, Bern, CH) joins us to discuss the prospective, multicentre, single-arm, postmarket MOTIV trial (NCT05406622; REVA Medical, Inc.), investigating the safety and effectiveness of the MOTIV sirolimus-eluting BVS verses balloon angioplasty for the treatment of infrapopliteal lesions in patients with symptomatic critical limb ischemia.

Interview Questions:
1. What is the reasoning behind the MOTIV trial?
2. Could you tell us about the unique features of the MOTIV BVS?
3. What was the study design and patient population?
4. What are the key outcomes?
5. How should these findings impact clinical practice?
6. What further research is needed in this area?

Recorded remotely from Bern, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: Mike Knight, Oliver Miles

Support: This is an independent interview produced by Radcliffe Vascular.